Testing AFN50 for hard-to-treat autoimmune diseases
Part of Immune system & allergy clinical trials.
This study tests an experimental drug called AFN50 for people with certain autoimmune diseases that have not responded to standard treatments. It aims to see if AFN50 can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 69 years old.
- You have one of these autoimmune diseases that hasn't gotten better with standard treatments: lupus, Sjögren's syndrome, myasthenia gravis, systemic sclerosis, inflammatory myopathy, or ANCA vasculitis.
- You have had active disease symptoms for at least 6 months, even while on medications like steroids or immunosuppressants.
- Your organ functions (blood counts, liver, kidneys, heart, lungs) meet certain minimum levels.
- You are not pregnant or breastfeeding, and agree to use birth control for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment (STR-P005) for autoimmune diseases. It aims to selectively target and deplete B cells that carry a specific marker, CD19, which may help reduce disease activity.
This study tests an experimental drug called STR-P005 for people with diseases that affect B cells, such as certain autoimmune or blood disorders. The goal is to see if the drug is safe and if it helps reduce your disease symptoms.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This study tests an investigational injection called AFN50 for people whose lupus (SLE) remains active despite standard treatments. The goal is to see if the drug can safely help control lupus symptoms better than current therapies alone.
This early-phase trial is testing an experimental injection called JY231 for people with certain autoimmune diseases like lupus and scleroderma that haven't improved with standard treatments. The aim is to see if this treatment can reduce disease activity and improve symptoms.
This trial is testing a new injection, NEUK203-215, in adults aged 18-65 with certain autoimmune diseases (like lupus, scleroderma, inflammatory myopathy, or a skin blistering condition) that have relapsed or not responded to standard therapy. The goal is to see if it is safe, tolerable, and may help control the disease.
Hear when a new Relapsed/Refractory Autoimmune Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.